The 1 mg Tirzepatide Dose: What the Evidence Actually Shows

What clinical trials established about the opening dose

The SURMOUNT-1 trial, published in the New England Journal of Medicine, tested tirzepatide at 5 mg, 10 mg and 15 mg in over 2,500 adults with obesity. Even the lowest dose tested in that trial (5 mg) produced meaningful average weight reduction over 72 weeks. What the trial design also revealed was that starting at a full therapeutic dose produced more GI side effects early on. The 2.5 mg starter dose that now appears in the SmPC was calibrated precisely to reduce those early weeks of nausea and discomfort, not to contribute directly to weight loss at that strength. In plain terms, the first four weeks on tirzepatide are about adjustment, not treatment in the therapeutic sense.

A 1 mg dose would sit well below that adjustment threshold. There is no published phase-3 evidence for it, no licensed product containing it, and no regulatory pathway through which a UK pharmacy could dispense it. The 2.5 mg starting dose is the floor set by Eli Lilly and endorsed by the MHRA, for good clinical reasons.

The six-rung licensed schedule and why each step matters

The authorised UK strengths (2.5, 5, 7.5, 10, 12.5 and 15 mg) form a deliberate ladder. Each step upward is typically taken after four weeks at the current dose, once your prescriber is satisfied that tolerance is reasonable. How the tirzepatide dose progression works in practice is one of the questions our clinical team fields most often: patients sometimes assume a higher dose is always better, but the target dose is the highest one you tolerate well, not necessarily the maximum. Plenty of people find their results at 5 mg or 7.5 mg and go no further.

What the SURMOUNT programme showed is that higher doses produced greater average reductions, around 20–21% of body weight at 15 mg over 72 weeks, cited in NICE's appraisal of tirzepatide (TA1026). But those figures came after months on the lower doses. The early rungs of the schedule aren't decoration; they are the clinical foundation the upper doses are built on. Skipping them, or seeking a sub-licensed 1 mg dose, misreads how the medicine actually works.

For a detailed look at what happens when the starter period ends, the 5 mg tirzepatide page covers the transition most people experience first, including what to expect as your body adjusts to a full therapeutic strength.

Where the 1 mg figure sometimes comes from

A few sources generate this query. Some compounding pharmacies (many of which operate outside the licensed supply chain) produce tirzepatide at non-standard doses, including strengths below 2.5 mg. These are not authorised products. The MHRA has warned publicly about unlicensed and counterfeit weight-loss medicines circulating online; large seizures of fake pens have included products falsely labelled as branded GLP-1 injections, some found to contain harmful substitutes. The Yellow Card scheme at yellowcard.mhra.gov.uk lets you report any suspect medicine or seller.

Another source is academic pharmacology literature, which occasionally studies tirzepatide at non-clinical concentrations. That research context does not translate into a patient dose. And occasionally, international dosing data (from studies using different protocols or early-phase designs) circulates without the UK-licensing caveat attached. None of it changes what a regulated UK prescriber can lawfully issue.

If you've come across a seller offering tirzepatide at 1 mg, that is a meaningful red flag. Legitimate supply in the UK runs through the authorised schedule, which includes 10 mg tirzepatide as one of the later licensed steps, via a pharmacy you can verify on the GPhC register. That check takes under a minute and is worth doing for any online pharmacy you consider using.

What eligibility actually looks like, and what comes next

The licensed eligibility criteria for tirzepatide in the UK (per the SmPC and NICE TA1026) are: adults with a BMI of 30 or above, or 27 or above alongside at least one weight-related condition such as high blood pressure, raised cholesterol, type 2 diabetes or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. BMI alone doesn't settle the question; a prescriber reviews the full clinical picture, including any contraindications and current medicines, before a prescription is issued.

The full Mounjaro overview covers the wider eligibility, mechanism and evidence picture if you want the broader context. For pricing and what a private consultation includes, the treatment page sets that out transparently. If you're ordering around a bank holiday or planning ahead for the end of the month, payday orders placed before 12pm on a working day are dispatched the same day once clinically approved, so timing the order to a weekday gives you the fastest route.

The NHS's patient-level guidance on tirzepatide, including side-effect information and what to tell your doctor, is available on the NHS tirzepatide medicines page, a practical reference before any consultation.